(Total Views: 341)
Posted On: 10/09/2025 8:33:11 AM
Post# of 158188
at least this one has a link to listen to webcast
https://www.cytodyn.com/newsroom/press-releas...x-investor
VANCOUVER, Washington, Oct. 09, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"
, a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including triple-negative breast cancer (TNBC) and metastatic colorectal cancer (mCRC), announced that CFO Robert E. Hoffman will present a corporate overview at the LD Micro Main Event XIX Investor Conference from October 19 – 21, 2025 at the Hotel Del Coronado in San Diego, California.
Presentation Date: Tuesday, October 21, 2025
Time: 9 a.m. PDT
Register to view presentation: Webcast Link
https://www.cytodyn.com/newsroom/press-releas...x-investor
VANCOUVER, Washington, Oct. 09, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"
, a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including triple-negative breast cancer (TNBC) and metastatic colorectal cancer (mCRC), announced that CFO Robert E. Hoffman will present a corporate overview at the LD Micro Main Event XIX Investor Conference from October 19 – 21, 2025 at the Hotel Del Coronado in San Diego, California. Presentation Date: Tuesday, October 21, 2025
Time: 9 a.m. PDT
Register to view presentation: Webcast Link
(4)
(0)
